Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 394.26 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 244.55K shares, a 65.28% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 149.71K shares, a 37.65% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 111.18K shares, a 34.02% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 507.11K shares, a 251.53% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.56M shares, a 138.10% increase from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 656.37K shares, a 104.22% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 321.40K shares, a 40.18% decline from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 537.26K shares, a 1.81% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 244.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | 394.26K shares 10-Q · filed 2026-07-29 | 505.45K shares derived: sum of 3 quarters · filed 2026-07-29 | 1.01M shares derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | 149.71K shares 10-Q · filed 2026-05-11 | 260.89K shares derived: sum of 2 quarters · filed 2026-05-11 | 768.01K shares derived: sum of 3 quarters · filed 2026-05-11 | 1.47M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 111.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 618.29K shares derived: sum of 2 quarters · filed 2026-03-02 | 1.32M shares derived: sum of 3 quarters · filed 2026-03-02 | 1.56M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 507.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.21M shares derived: sum of 2 quarters · filed 2025-11-05 | 1.45M shares 10-Q · filed 2025-11-05 | 1.62M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 704.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | 944.53K shares 10-Q · filed 2025-07-28 | 1.11M shares derived: sum of 3 quarters · filed 2025-07-28 | 1.26M shares derived: sum of 4 quarters · filed 2025-07-28 |
| 2025-03-31 | 240.10K shares 10-Q · filed 2025-05-08 | 408.60K shares derived: sum of 2 quarters · filed 2025-05-08 | 552.86K shares derived: sum of 3 quarters · filed 2025-05-08 | 598.55K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 168.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 312.76K shares derived: sum of 2 quarters · filed 2025-02-27 | 358.45K shares derived: sum of 3 quarters · filed 2025-02-27 | 656.37K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 144.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 189.95K shares derived: sum of 2 quarters · filed 2024-11-12 | 487.87K shares 10-Q · filed 2024-11-12 | 539.21K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 45.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 343.61K shares 10-Q · filed 2024-08-12 | 394.95K shares derived: sum of 3 quarters · filed 2024-08-12 | 507.06K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 297.92K shares 10-Q · filed 2024-05-02 | 349.27K shares derived: sum of 2 quarters · filed 2024-05-02 | 461.38K shares derived: sum of 3 quarters · filed 2024-05-02 | 543.26K shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 51.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 163.45K shares derived: sum of 2 quarters · filed 2024-03-05 | 245.34K shares derived: sum of 3 quarters · filed 2024-03-05 | 321.40K shares 10-K · filed 2024-03-05 |
| 2023-09-30 | 112.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | 194.00K shares derived: sum of 2 quarters · filed 2023-10-30 | 270.06K shares 10-Q · filed 2023-10-30 | 408.24K shares derived: sum of 4 quarters · filed 2023-10-30 |
| 2023-06-30 | 81.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 157.95K shares 10-Q · filed 2023-08-03 | 296.13K shares derived: sum of 3 quarters · filed 2023-08-03 | 367.79K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 76.06K shares 10-Q · filed 2023-05-11 | 214.24K shares derived: sum of 2 quarters · filed 2023-05-11 | 285.90K shares derived: sum of 3 quarters · filed 2023-05-11 | 430.54K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 138.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 209.84K shares derived: sum of 2 quarters · filed 2023-03-02 | 354.48K shares derived: sum of 3 quarters · filed 2023-03-02 | 537.26K shares 10-K · filed 2023-03-02 |
| 2022-09-30 | 71.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 216.29K shares derived: sum of 2 quarters · filed 2022-11-03 | 399.08K shares 10-Q · filed 2022-11-03 | 811.08K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 144.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 327.43K shares 10-Q · filed 2022-08-04 | 739.42K shares derived: sum of 3 quarters · filed 2022-08-04 | 863.92K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 182.79K shares 10-Q · filed 2022-05-02 | 594.78K shares derived: sum of 2 quarters · filed 2022-05-02 | 719.28K shares derived: sum of 3 quarters · filed 2022-05-02 | |
| 2021-12-31 | 411.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 536.49K shares derived: sum of 2 quarters · filed 2022-03-10 | 547.16K shares 10-K · filed 2022-03-10 | |
| 2021-09-30 | 124.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 135.16K shares 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | 10.66K shares 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 110.48K shares 10-K · filed 2021-03-04 | ||
| 2020-09-30 | 110.48K shares 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |